De-escalation trials in multiple myeloma: past, present and future

Area of Science:

• Hematology
• Oncology
• Clinical Therapeutics

Background:

• Therapeutic approaches for multiple myeloma (MM) are evolving with new agents, including immunotherapies, used earlier in treatment.
• Prolonged MM treatment can lead to significant toxicity and patient burden.
• De-escalation is a new phase focused on maintaining durable disease control with reduced treatment intensity.

Purpose of the Study:

• To synthesize emerging evidence on de-escalation strategies in multiple myeloma.
• To identify patient populations and treatment components suitable for de-escalation.
• To highlight challenges and uncertainties in implementing de-escalation approaches.

Main Methods:

• Review of emerging evidence on various de-escalation strategies.
• Analysis of contemporary clinical trials defining patient populations for de-escalation.
• Discussion of methodological and implementation challenges.

Main Results:

• Multiple de-escalation strategies are being explored, including dose modification, agent withdrawal, fixed-duration therapy, minimal residual disease-adapted treatment, and CAR T-cell infusion.
• Current trials are beginning to identify suitable patient groups and treatment components for de-escalation.
• Significant uncertainties remain regarding monitoring, re-treatment criteria, and feasibility.

Conclusions:

• De-escalation of therapy in multiple myeloma is a promising approach to balance efficacy and tolerability.
• Further research and careful trial design are needed to overcome implementation challenges.
• Successful translation requires stakeholder involvement and robust monitoring strategies.